Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.68 USD
0.00 (0.37%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $0.69 +0.01 (1.85%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Hepion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 48 | 45 | 30 | 20 | 8 |
Income After Depreciation & Amortization | -48 | -45 | -30 | -20 | -8 |
Non-Operating Income | -1 | 0 | -2 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -49 | -45 | -33 | -20 | -8 |
Income Taxes | 0 | -3 | 0 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -49 | -42 | -33 | -20 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -49 | -42 | -33 | -20 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -45 | -44 | -30 | -20 | -7 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -48 | -45 | -30 | -20 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.97 | NA | 3.52 | 0.48 | 0.10 |
Diluted EPS Before Non-Recurring Items | -12.32 | NA | -9.40 | -42.00 | -119.00 |
Diluted Net EPS (GAAP) | -12.32 | -11.80 | -9.40 | -42.00 | -119.00 |
Fiscal Year end for Hepion Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 8.51 | 5.18 | 10.41 | 10.67 | 14.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.51 | -5.18 | -10.41 | -10.67 | -14.16 |
Non-Operating Income | 4.53 | -0.64 | -1.06 | 0.14 | 0.09 |
Interest Expense | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -3.93 | -5.82 | -11.47 | -10.53 | -14.08 |
Income Taxes | 0.00 | -2.97 | -0.41 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.93 | -2.85 | -11.06 | -10.53 | -14.08 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.93 | -2.85 | -11.06 | -10.53 | -14.08 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5.80 | 5.07 | 3.97 | 3.84 | 3.83 |
Diluted EPS Before Non-Recurring Items | -0.68 | -0.56 | -2.42 | -2.74 | -3.68 |
Diluted Net EPS (GAAP) | -0.68 | -0.56 | -2.42 | -2.74 | -3.68 |